New study tests simpler procedure to stop post-miscarriage bleeding
NCT ID NCT07206342
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the best way to stop heavy bleeding after a miscarriage. It compares two procedures: one that temporarily blocks blood vessels with a gelatin material, and another that does the same but also removes tissue from the womb. About 110 participants will be followed for a year to see which method works better and how it affects future fertility.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- resorbable gelatin embolization
- What this could lead to
- If successful, this could establish a simpler, less invasive standard treatment for post-miscarriage bleeding, potentially preserving fertility.
- What could go wrong
- This is a small, early-stage trial (110 participants) comparing two procedures; one may not be clearly better, and results may not apply to all patients. Risks include bleeding recurrence or complications from the procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient who experienced a miscarriage within 3 months * Patient with gynecological bleeding * Patient presenting with hypervascularized uterine retention with negative Doppler ultrasound findings (endometrial hypervascularization with 1) systolic peak velocity greater than 70 cm/s and/or 2) resistance index (RI) within the retention \< 0.5) * Patient affiliated to french social security * Patient who has signed the written informed consent form Exclusion Criteria: * Patient presenting to the emergency department with hemorrhagic shock: systolic blood pressure \< 90 mmHg associated with tachycardia \> 120 bpm * Severe renal failure (glomerular filtration rate \< 30 mL/min) * Medical history of severe allergy to iodinated contrast media * Severe coagulation disorders (platelets \<50G/L, PT \< 50%) * Anticoagulant and/or antiplatelet agent that cannot be discontinued a few days before the procedure * Patient referred to in Articles L1121-5, L1121-6, and L1121-8 of the French Public Health Code * Staff with a hierarchical relationship to the principal investigator * Patient in the exclusion period of another study * Patient cannot be contacted in an emergency * Participation in other interventional studies during the study period
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hemorrhage, obstetric are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Grenoble Alpes
Grenoble, 38000, France
-
CHU de Bordeaux
Bordeaux, 33000, France
-
CHU de Clermont-Ferrand-Gabriel Montpied
Clermont-Ferrand, 63000, France
-
CHU de St Etienne-Hôpital Nord
Saint-Etienne, 42000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.